Inovio Pharmaceuticals, Biogen, Guess? Downgraded

Inovio Pharmaceuticals, Biogen, and Guess? received bearish analyst attention ahead of today's open

Mar 16, 2017 at 10:35 AM
facebook twitter linkedin

Analysts are weighing in on drug stocks Inovio Pharmaceuticals Inc (NASDAQ:INO) and Biogen Inc (NASDAQ:BIIB), as well as apparel retailer Guess?, Inc. (NYSE:GES). Here's a quick roundup of today's bearish brokerage notes on INO, BIIB, and GES shares.

Inovio Sinks After Fourth-Quarter Results

INO is down 8.7% this morning at $6.27, following the company's fourth-quarter earnings release. Analysts have had mixed reactions, with Piper Jaffray downgrading the shares to "neutral" from "overweight" and cutting its price target to $9 from $13, while Maxim raised its opinion to "buy" from "hold." It's been a lackluster year for Inovio Pharmaceuticals Inc stock, with the shares grinding lower since their high of $11.69 from last April. These struggles are just fine with short sellers, though, since they currently control 14.8% of INO's total float. 

Downgrades Hit Biogen Stock 

Bearish notes out of Morgan Stanley and Leerink have BIIB stock down 4.5% today at $279.39. The former firm downgraded the shares to "equal weight" from "overweight," cutting its price target to $305 from $369, saying the decision "is not a downside call, but a timing call." Leerink, meanwhile, cut Biogen Inc to "market perform" from "outperform," and lowered its price target by $5 to $300, citing limited catalysts and increasing competition. While BIIB shares still sport a 23% year-over-year gain, they're on pace to close below their 20-day moving average for the first time since Feb. 1, due to a recent round of bearish analyst attention

Guess? Continues Long-Term Downtrend After Earnings

GES hit an eight-year low of $10.29 out of the gate, and was last seen 18.5% lower at $11.20, after the company failed to meet Wall Street's fourth-quarter earnings expectations. At least five price-target cuts have since come through, with the lowest target of $9 coming from Mizuho. Guess?, Inc. has been trending lower for several years now, and short sellers continue to bet against the struggling retail stock. After increasing 22% in the last two reporting periods, short interest on Guess stock now represents roughly one-fifth of its available float. 

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners